Barina Khan

Barina Khan

Auto-generated profile, based on publicly available information

Barina Khan

Karachi Medical and Dental College, Karachi, Pakistan

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2025 in Croatian Medical Journal
Verified
Journal Article
Open access
PDF file
BKBarina Khan
Barina Khan

4 February 2026 in Nutrition Research
Verified
Journal Article
Closed access
SKSaim Mahmood Khan
Saim Mahmood Khan
JHJawairya Muhammad Hussain
Jawairya Muhammad Hussain
BKBarina Khan
Barina Khan
ASAbdullah Saad
Abdullah Saad
JMJaweria Mehboob
Jaweria Mehboob
RHRida Hashim
Rida Hashim

3 September 2026 in Journal of Artificial Organs
Verified
Journal Article
Closed access
PDF file
BKBarina Khan
Barina Khan

22 May 2026 in Journal of Community Medicine and Health Solutions
Verified
Journal Article
Open access
PDF file
BKBarina Khan
Barina Khan
MAMahnoor Abbas
Mahnoor Abbas
HSHifza Shahzad
Hifza Shahzad
LALubaba Amaim
Lubaba Amaim
Hereditary angioedema (HAE) is a rare autosomal dominant disorder characterized by recurrent, potentially life-threatening episodes of angioedema affecting the skin, gastrointestinal tract, and airway. It results from dysregulation of the kallikrein–kinin system due to C1-esterase inhibitor deficiency or dysfunction, leading to excessive bradykinin production and increased vascular permeability. Despite advances in prophylactic therapies such as C1-INH replacement, kallikrein inhibitors, and bradykinin receptor antagonists, limitations including frequent dosing, breakthrough attacks, and variable response, remain. Garadacimab is a novel fully human monoclonal antibody that targets activated factor XII (FXIIa), inhibiting initiation of the contact activation pathway upstream of bradykinin generation. Blocking FXIIa, it prevents prekallikrein activation and downstream inflammatory cascade amplification. Clinical trials across Phase 1–3 studies demonstrate consistent pharmacodynamic target engagement, dose-dependent suppression of the kallikrein pathway, and significant reductions in attack rates, with a substantial proportion of patients remaining attack-free. The pivotal Phase 3 (VANGUARD) study further confirmed sustained efficacy and meaningful improvements in health-related quality of life. Garadacimab has shown a favorable safety profile, with mostly mild to moderate adverse events and no major safety concerns. Its long half-life enables once-monthly subcutaneous administration, potentially improving adherence and reducing treatment burden compared with existing therapies. Overall, FXIIa inhibition with Garadacimab represents a promising upstream prophylactic strategy for HAE, addressing key limitations of current treatments and offering durable disease control. Further real-world and comparative studies are needed to define its long-term role in clinical practice and broader applicability in contact system–mediated disorders.

9 July 2026 in Naunyn-Schmiedeberg's Archives of Pharmacology
Verified
Journal Article
Closed access
ASAbdullah Saad
Abdullah Saad
BKBarina Khan
Barina Khan
ABAhmed Reda Bahr
Ahmed Reda Bahr
MAMostafa Abdelhakiem
Mostafa Abdelhakiem

31 August 2026 in Journal of Community Medicine and Health Solutions
Verified
Journal Article
Open access
PDF file
ASAneesh Kumar Sangtiani
Aneesh Kumar Sangtiani
BKBarina Khan
Barina Khan
SJSundal Javed
Sundal Javed
SASariya Aamir
Sariya Aamir
Precision medicine is increasingly shaping clinical practice in both hematology and cardiology by promoting therapies and diagnostics rooted in disease mechanisms. In immune thrombocytopenia (ITP), rilzabrutinib, an oral Bruton tyrosine kinase inhibitor, represents a targeted strategy that addresses key drivers of the disease. By reducing autoantibody production and limiting immune-mediated platelet destruction, it has demonstrated sustained platelet responses while potentially avoiding the broader immunosuppressive effects seen with conventional treatments. Its mechanism also raises the possibility of application in other autoimmune conditions. In cardiology, attention has turned toward pericoronary adipose tissue (PCAT) attenuation measured on coronary computed tomography angiography as a marker of coronary inflammation. Unlike traditional imaging that focuses primarily on luminal narrowing, PCAT assessment offers insight into vascular inflammatory activity and may enhance cardiovascular risk prediction. Although these developments are promising, important challenges remain, including long-term tolerability, cost considerations, and technical standardization. Together, these advances reflect both the opportunities and the complexities involved in translating precision medicine from theory into everyday clinical care.